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Background: Our objective was to obtain estimates of the impact of the Dutch vaccination programme on
medication use, outpatient visits, hospitalization and mortality at age 65. Methods: We linked population-wide
mortality, hospitalization and municipality registries to identify influenza-related deaths and hospitalizations, and
used health interview surveys to identify medication use and outpatient visits during 1996–2008. We applied a
regression discontinuity design to estimate the intention-to-treat effect of the personal invitation for a free
influenza vaccination sent to every Dutch inhabitant at age 65 years on each of the outcomes, separately in
influenza-epidemic and non-epidemic months. Results: Invitation receipt for free influenza vaccination at age
65 led to a 9.8 percentage points [95% confidence interval (CI) = 3.5 to16.1; P< 0.01] rise in influenza vaccination.
During influenza-epidemic months, it was associated with 1.5 fewer influenza/pneumonia deaths per 100 000
individuals (95% CI = 3.1 to 0.0; P=0.05), a 15 percentage point lower probability to use prescribed
medicines (95% CI = 28 to 3; P=0.02) and 0.13 fewer General Practitioner (GP) visits per month (95% CI =
0.28 to 0.02; P=0.09), while the association with hospitalizations due to influenza/pneumonia was small and
imprecisely estimated (seven more hospitalizations per 100 000 individuals, 95% CI = 20 to 33; P=0.63). No
associations were found with any outcomes during non-epidemic months. Conclusions: Personal invitations for
a free influenza vaccination sent to every Dutch inhabitant at age 65 took pressure off primary health care but had
small effects on hospitalizations and mortality.
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Introduction
Seasonal influenza may lead to excess healthcare use, severe illnessand sometimes death among individuals aged 65 and older.1
Most countries recommend annual seasonal influenza vaccination
to reduce the burden of influenza in this age group.2,3 However,
the effectiveness of vaccination for people aged 65+ has come
under scrutiny during the last decade. A meta-analysis of
randomized controlled trials (RCT) concluded that good evidence
of the impact of vaccines on pneumonia, hospitalization and
mortality is lacking for this fragile age group,1 and new RCTs are
not feasible due to the near universal vaccination recommendation
for people aged 65+.1 This has led to a greater reliance on evidence
from observational studies which are more prone to selection and
confounding biases.4–6
Only few observational studies on vaccination effectiveness have
addressed biases due to non-random treatment allocation and/or
unobserved confounders. Applying the relatively new test-negative
study design alleviates, but does not completely remove, concerns
about these biases.1,7–9 Studies applying instrumental variable (IV)
analysis have been unsuccessful: using prevalence of chronic
diseases10,11 or vaccination coverage11,12 as IV’s do not account for
confounding due to co-morbidities11,13 or herd immunity.14
Exploiting variation in influenza incidence over time15,16 fails to
correct for selection and confounding due to time variation in
vaccination take-up and herd immunity.
The overall effect of a vaccination programme relates to the
difference in incidence or health outcomes between a targeted
population and a comparable non-targeted population.17 It
depends on vaccination effectiveness, vaccination coverage and
herd immunity. Our objective was to obtain estimates of the
overall effect of the Dutch vaccination programme on mortality
and hospitalization for influenza/pneumonia and respiratory
diseases, and medication use and physician visits from population-
based registries (and representative survey data) that are not affected
by confounding and selection biases. These biases may arise when
comparing vaccinated with non-vaccinated individuals,6–9 epidemic
and non-epidemic periods15,16 or imposing the untestable
exogeneity assumption underlying IVs.10–14 We used a regression
discontinuity design (RDD)18–20 that exploits the age eligibility
rules of the Dutch free vaccination policy between 1996 and 2008
to estimate the intention-to-treat effect of receipt of a personal
invitation for a free influenza vaccination sent to every Dutch
inhabitant over 65 years. Separate estimation in epidemic and non-
epidemic months provided an internal validity check of the
identifying assumptions of RDD.
Methods
Setting
Before 1996, free influenza vaccination in The Netherlands was
targeted to high-risk individuals, defined as people with chronic
disorders, such as diabetes, cardiovascular and pulmonary
conditions, renal disease, immune dysfunctions and HIV/AIDS
patients. All other individuals had to pay the full cost of 40 euro
(in 2018 purchasing power).
In 1996, the vaccination policy was reformed into a population-
wide programme and all individuals aged 65 and above received a
personalized invitation letter for free influenza vaccination. In
addition, barriers to take-up vaccination were further reduced for
programme-eligible individuals by providing GPs with their own
stock of vaccines and by providing remuneration and supporting
agencies to healthcare providers in charge of the vaccination
programme. Receipt of an invitation letter in September/October
depended on whether the individual would be 65 on May 1st of
the next calendar year (‘programme-age’). Hence, all individuals
turning 65 between September/October and May 1st received the
invitation letter when their actual calendar age was 64; thereby
preventing that invitation receipt coincided with eligibility for
other social programmes, such as pension benefits.
Between 1996 and 2008, vaccination rates of the target group
reached 75–80% in The Netherlands and were among the highest
in Europe.21,22 Prescribed medicines, general and specialist physician
services, and hospital care were available to everyone through
comprehensive social health insurance.
Study design
RDD18–20 exploits the insight that the receipt of a personal invitation
for a free flu shot cannot be influenced as every individual inevitably
becomes eligible for the free influenza programme when they turn
65. When invitation receipt leads to a discontinuous increase in
vaccination behaviour at age 65, but no discontinuity in any other
determinant of mortality and medical care use, RDD deals with
confounding and selection biases (Supplementary appendix S4).23–
25 Individuals slightly younger and older than 65 can then be
considered identical, except for the receipt of an invitation for a
free flu shot. The lack of an incentive to postpone vaccination the
year before turning eligible, as antibodies decline over time and the
influenza virus mutates every year, further adds to the strength of the
RDD research design.
We applied RDD separately in epidemic and non-epidemic
months.15,16 Existence of a discontinuity at ‘programme-age’ 65 in
epidemic months and absence of a discontinuity in the other months
is then indicative of the effectiveness of the free influenza vaccination
programme for mortality, medical care and medication outcomes at
age 65.
Study population and data sources
We used two datasets: annual cross-sectional health interview
surveys (HIS) for 1997–2008 and linked administrative data
sources from Statistics Netherlands for 1996–2008. As stipulated in
the data agreement, Statistics Netherlands pre-viewed the findings of
all analyses in this project prior to publication.
HIS informed on medication use, physician visits and vaccination
behaviour. Prescribed and non-prescribed medicine uses during the
last month were reported as binary variables. The number of GP
visits and the number of visits to the medical specialist during the
last 2 months were rescaled into monthly figures. Vaccination take-
up was self-reported, and vaccinated individuals reported the reason
for vaccination take-up.
The linked administrative databases included the mortality registry
for 1996–2008, the hospital registry for 1996–2005, and the
municipality registry for 1996–2008 which contained demographic
information for all inhabitants of The Netherlands. We retrieved the
timing of deaths related to influenza/pneumonia (ICD 10 codes J09–
J19 for primary or secondary cause of death) and all respiratory
problems (ICD 10 codes J00–J99 for primary or secondary cause of
death) from the mortality registry, and the timing of hospitalizations
due to influenza/pneumonia (ICD 9 codes 480–488) and due to all
respiratory problems (ICD 9 codes 460–519) from the hospital
registry.
In the HIS and the registries, actual date of birth was used to
compute ‘programme-age’ at May 1st of any given year, and
‘programme-age’ was defined in years and months. The Imbens
and Kalyanaraman23 criterion and Lee and Lemieux18 guidelines
recommended removing individuals whose ‘programme-age’ was
younger than 63 or older than 66 to ensure that included individuals
were sufficiently close to the ‘programme-age’ threshold of 65
(Supplementary appendix S4).23–25
Influenza seasons were defined to start 1 September and end 31
August in the following year (1997/98–2007/08 in the HIS; 1996/97–
2005/06 in the hospital registry; and 1996/97–2007/08 in the
mortality register). We subdivided each influenza season into
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epidemic and non-epidemic months using data from the National
Institute for Public Health and the Environment. Epidemic months
are defined as months in which there was at least 1 week with more
than 5% of the year-round influenza incidence (Supplementary
appendix S3).14,26
Every month, HIS collected approximately one-twelfth of the
annual number of observations, and year, month of interview and
recall period were used to assign individuals to influenza seasons and
(non-)epidemic months within influenza seasons. The data
construction was different in the hospital and mortality register
data. In both registries, we considered for each influenza season all
individuals that were alive at the start of that influenza season. In the
hospital registry, the timing of admission was used to construct
binary indicators of any hospitalization during the epidemic and
non-epidemic months. Comparing epidemic with non-epidemic
months in the mortality register leads to a mechanical effect as
dying in the epidemic period makes it impossible to die again in
the non-epidemic months thereafter. Therefore, the non-epidemic
period covered mortality (binary variable) throughout the entire
influenza season, and the epidemic period considered mortality
(binary variable) during the epidemic months among individuals
that were alive at the start of that epidemic period. The same
mechanical effect might make it impossible to be admitted to the
hospital in the months after death; but the estimates for the
mortality outcomes will inform on the sign and magnitude of the
bias. Since hospitalizations and mortality may occur in the month
following the influenza infection,27 we extended the epidemic period
in both registries with 1 month.
More details are provided in Supplementary figures S1 and S2,
and Supplementary appendices S1–S3.14,26,28
Statistical analyses
We used ordinary least squares (OLS) to model medication use,
physician visits, hospitalization and mortality as a linear function
of ‘programme-age’, a binary variable for ‘programme-age’ equal or
older than 65, and an interaction between this binary variable and
‘programme-age’ to allow for differential trends at each side of the
cut-off (RDD regression). The OLS coefficients of the binary
indicator and its associated 95% CI and P values provided the
intention-to-treat estimates of the receipt of an invitation for a
free flu shot, i.e. the divergence in medication use/physician visits/
hospitalization/mortality at opposite sides of, but very close to the
‘programme-age’ threshold of 65. The estimates for epidemic and
non-epidemic months were directly comparable in the HIS as
medication use and physician visits were measured/rescaled in
monthly figures, but the estimates for the epidemic and non-
epidemic months derived from the registries were only comparable
after dividing by the (observation-weighted) average number of
months in the (non-)epidemic period (Supplementary appendix
S4).23–25 Estimates of the relative magnitudes were obtained after
dividing the intention-to-treat estimate by the predicted value of
the dependent variable at ‘programme-age’ 65. In order to ease
the interpretation of the intention-to-treat estimates, we further
ran a pooled RDD regression to establish the discontinuity in
vaccination take-up at ‘programme-age’ 65.
All RDD regression models were adjusted for the following
potential confounders. In the HIS, we controlled for gender,
education (primary, lower secondary, upper secondary and post-
secondary), household composition (single, couple, household
with children and other), the number of household members,
influenza season, population density (inhabitants/km2: below 500,
between 500 and 2500 and above 2500), pre-existing medical
conditions (asthma, heart disease, liver disease, kidney disease,
diabetes, rheumatism and cancer), and presence of a long-term
illness, infirmity or handicap. In the registries, data availability
limited adjustment to gender and influenza season. The HIS-based
analyses used the sample weights provided by HIS, and robust
standard errors were clustered at the year-municipality level to
mimic the sampling design. Analyses with the registries used
robust standard errors clustered at the individual level.
We also carried out several sensitivity and robustness checks to
assess the validity of the RDD. First, we checked for discontinuities
in vaccination take-up at ‘artificial’ cut-offs and assessed whether
behaviours, such as prevention, health behaviour and altruism,
changed when becoming eligible for free influenza vaccination. We
further tested for heaping bias,24 discontinuities in the control
variables, and re-estimated all RDD models with different
windows around the ‘programme-age’ cut-off, alternative
assumptions about the trends in vaccination take-up left and right
of the cut-off, and assuming the logistic regression model. Finally,
we checked whether missing data in the HIS could bias our
estimates. Supplementary appendix S4 provides more details.23–25
Results
Subjects
We observed mortality and hospitalization for the entire Dutch
population in the ‘programme-age’ bandwidth 63–66 during the
course of respectively 12 and 10 influenza seasons. For this group,
table 1 indicates that, on average, 7 out of 100 000 individuals died
every month from influenza/pneumonia during the epidemic
period, and 6 out of 100 000 during the non-epidemic period.
These monthly numbers were higher for respiratory hospitalization:
80 and 56 out of 100 000. We also studied 3183 individuals in the
HIS sample during 11 influenza-seasons and observed slightly more
GP visits and medication use during epidemic as compared with
non-epidemic months. In total, 40% decided to vaccinate against
influenza (Supplementary table S1). Additional characteristics of the
HIS sample and linked mortality and hospitalization registries are
presented in Supplementary table S1.
Age discontinuity in vaccination take-up
Individuals whose ‘programme-age’ turned 65 were 9.8 percentage
points (95% CI = 3.5 to 16.1; P < 0.01) more likely to vaccinate
(Supplementary table S2). We found a coinciding increase
(decrease) in the relative frequency of written invitations from the
GP (vaccination on own initiative; Supplementary table S2).
Sensitivity analyses confirmed the validity of the RDD, i.e. no
discontinuities in vaccination take-up at artificial ‘programme-
ages’; and prevention and health behaviour did not change when
becoming eligible for free influenza vaccination (Supplementary
table S2).
Impact of receiving a free influenza invitation on
medication, medical care use and mortality
Table 2 shows the change in medication use, physician visits,
hospitalizations and mortality after receiving an invitation for free
influenza vaccination at ‘programme-age’ 65. We found no evidence
for age discontinuities in medicine use and physician visits
during non-epidemic months. During epidemic months, some
discontinuities emerged: a 15 percentage point lower probability
to use prescribed medicines (95% CI = 28 to 3; P = 0.02) and
0.13 fewer GP visits (95% CI = 0.28 to 0.02; P = 0.09) per month,
corresponding to relative reductions of 20% and 26%.
The hospitalization indicators showed no evidence of an age
discontinuity at ‘programme-age’ 65 in epidemic and non-
epidemic months, and the same was true for respiratory deaths.
Every month, 1.5 influenza/pneumonia deaths per 100 000
individuals (95% CI = 3.1 to 0.0; P = 0.05) were averted
during epidemic months—a 20% relative reduction—while the
discontinuity was very small during non-epidemic months (0.3
per 100 000, 95% CI = 1.0 to 0.4; P = 0.41)—a 5% relative
reduction.
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Table 1 Characteristics of the Study Population in the HIS and the linked mortality and hospitalization registries during epidemic and non-
epidemic months (‘programme-age’ bandwidth 63–66)
Outcomes during epidemic monthsa Outcomes during non-epidemic monthsa
Characteristics nb %c nb %c
HISd (1997/98–2007/08)
Medication use
Non-prescribed medicines 724 44 2459 40
Prescribed medicines 724 65 2459 64
Physician visits
GP visits,e mean (SD) 984 0.37 (0.68) 2197 0.31 (0.49)
Medical specialist visits,e mean (SD) 984 0.17 (0.40) 2198 0.19 (0.47)
Hospitalization registry (1996/97–2005/06)
Influenza/pneumonia hospitalizatione 5 831 941 0.018 5831941 0.013
Respiratory hospitalizatione 5 831 941 0.080 5831941 0.056
Mortality registry (1996/97–2007/08)
Influenza/pneumonia deathse 6 463 524 0.007 7183332 0.006
Respiratory deathse 6 463 524 0.017 7183332 0.015
HIS, Health Interview Survey.
aEpidemic months are months in which there is at least 1week in which >5% of the year-round influenza incidence occurs. The epidemic
period is extended with 1month for non-prescribed and prescribed medicine use and influenza/pneumonia and respiratory hospitalization;
and with 2months for GP and medical specialist visits. For influenza/pneumonia and respiratory deaths, the epidemic period is extended
with 1month; and the non-epidemic period coincides with the entire influenza season (Supplementary appendix S3).
bNumber of observations. Every month, HIS collected one-twelfth of the annual number of observations, leading to a different number of
observations in epidemic and non-epidemic months. In addition, the epidemic (non-epidemic) period was extended (shortened) with the
length of the recall period—1month for medication use and 2months for physician visits—and there were some missing data (consult
section Study population and data sources, Supplementary appendices S1 and S3, and Supplementary figure S1 for more details). In the
epidemic and non-epidemics months of the hospitalization registry and the non-epidemic months in the mortality registry, the included
observations are all individuals that were alive at the start of an influenza season. The observations in the epidemic months of the mortality
registry coincide with all individuals alive at the start of the epidemic period (consult section Study population and data sources,
Supplementary appendix S2, and Supplementary figure S2 for more details).
cPercentage, unless indicated otherwise.
dAll percentages, means and standard deviations were calculated using the sampling weights provided by HIS. The number of observations
is the actual unweighted number of observations.
eRescaled to monthly figures (Supplementary appendix S4).
Table 2 Impact of invitation for a free flu shot on medication, medical care use and mortality at age 65 (‘program-age’ bandwidth between
63 and 66)a,b
Epidemic period (95% CI)c P-value Non-epidemic period (95% CI)c P-value
HIS (1997/98–2007/08)
Non-prescribed medicines 0.077 (0.217 to 0.064) 0.28 0.018 (0.098 to 0.061) 0.65
Prescribed medicines 0.151 (0.278 to 0.025) 0.02 0.050 (0.119 to 0.019) 0.15
GP visitsd 0.131 (0.283 to 0.021) 0.09 0.020 (0.065 to 0.106) 0.64
Medical specialist visitsd 0.064 (0.159 to 0.031) 0.18 0.020 (0.065 to 0.104) 0.65
Hospitalization registry (1996/97–2005/06)
Influenza/pneumonia hospitalizationd 0.000007 (0.000020 to 0.000033) 0.63 0.000000 (0.000013 to 0.000012) 0.98
Respiratory hospitalizationd 0.000046 (0.000010 to 0.000101) 0.11 0.000012 (0.000038 to 0.000013) 0.34
Mortality registry (1996/97–2007/08)
Influenza/pneumonia deathsd 0.000015 (0.000031 to 0.000000) 0.05 0.000003 (0.000010 to 0.000004) 0.41
Respiratory deathsd 0.000017 (0.000041 to 0.000007) 0.16 0.000002 (0.000012 to 0.000009) 0.75
HIS, Health Interview Survey.
aEach row represents an age discontinuity obtained from a separate OLS regression. For HIS, sampling weights provided by HIS were used.
We allowed for linear trends in ‘programme-age’ that can vary on each side of the ‘programme-age’ cut-off. All HIS analyses were
controlled for differences in sex, being member of a risk group based on pre-existing medical conditions, education, household composition
and size, influenza season, population density, and presence of chronic illness. Analyses on the registries were controlled for differences in
sex and influenza season. The number of observations is presented in table 1. All age discontinuities are expressed as percentage point
changes in probabilities per month, except for GP and medical specialist visits which are expressed as absolute changes in the number of
visits per month.
bEpidemic months are months in which there is at least 1week in which >5% of the year-round influenza incidence occurs. The epidemic
period is extended (compressed) with 1month for non-prescribed and prescribed medicine use and influenza/pneumonia and respiratory
hospitalization; and with 2months for GP and medical specialist visits. For influenza/pneumonia or respiratory deaths, the epidemic period
is extended with 1month; and the non-epidemic period coincides with the entire influenza season (Supplementary appendix S3).
cAdjusted for clustering at the wave-municipality level in the HIS and adjusted for clustering at the individual level in the registries.
dRescaled to monthly figures.
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Supplementary appendix S4 and Supplementary tables S3 and S4
confirm robustness of these estimates to the specification of the
RDD models (window, functional form trends and logistic
regression), heaping bias, discontinuities in the control variables
and missing data.23–25
Discussion
We found that the Dutch policy to invite every individual aged 65 or
above for free influenza vaccination was associated with reduced
mortality from influenza and pneumonia, GP visits and prescribed
medication use; but had no association with mortality from all
respiratory diseases, hospitalizations, medical specialist visits and
non-prescribed medication use. During an epidemic month, there
were 1.5 fewer influenza/pneumonia deaths per 100 000 individuals
(95% CI = 3.1 to 0.0; P = 0.05), a 15 percentage point lower
probability to use prescribed medicines (95% CI = 28 to 3;
P = 0.02) and 0.13 fewer GP visits (95% CI = 0.28 to 0.02;
P = 0.09) at ‘programme-age’ 65, corresponding to relative
reductions of 20%, 20% and 26%. During non-epidemic months,
none of the outcome variables were associated with the receipt of an
invitation for a free flu shot.
Influenza vaccination among individuals aged 65 and older is
recommended in most developed countries2,3 as previous studies
have indicated that the flu shot protects the elderly from death
during epidemic months.1,4,5 We confirm that influenza and
pneumonia deaths reduce after receipt of an invitation for free
influenza vaccination, but the estimated mortality reduction is
very small, also in contrast to previous findings.29,30 The absence
of an effect on influenza/pneumonia/respiratory hospitalizations, for
which previously risk reductions between 21% and 32% have been
reported using observational data,31–33 is in line with modest levels
of vaccination effectiveness at age 65; while the estimated reductions
of GP visits and prescribed medicines suggest that the Dutch free
vaccination policy primarily reduces primary care usage. The savings
in terms of reduced GP visits alone, even without accounting for
prescribed medicines, more than compensate for the cost of the
Dutch influenza vaccination programme. A back-of-the envelope
calculation for influenza season 2003/04, for example, indicates
that the expected number of averted GP visits per individual
(0.131 during four epidemic months and + 0.020 during eight
non-epidemic months) multiplied with a 20.20 euro savings per
averted GP visit34 outweighs the total cost of the influenza
vaccination programme which equalled 12.40 euro per vaccinated
individual35 times the increased probability that an individual
vaccinates (+0.098), leading to net savings of 6.14 euro per invited
individual at age 65, i.e. 20.20 * [0.131 * 4–0.020 * 8] – 12.40 * 0.098
(table 2, Supplementary table S2 and Supplementary appendices S3
and S4).14,23–26 In fact, all together, our findings suggest that earlier
studies of likely suffered from residual confounding and selection
biases, while our study of the impact of the Dutch vaccination
programme stresses the additional importance of reduced primary
care costs.
The most important strength of our study included the use of
population-based registries for hospitalization and mortality
outcomes in combination with a research design that allows
overcoming confounding and selection biases.36 To our
knowledge, our study was the first to use an RDD approach to
analyze a vaccination programme’s effectiveness against health and
healthcare outcomes; avoiding biases from comparing vaccinated
with non-vaccinated individuals,1–5,29–33 epidemic and non-
epidemic months/influenza seasons,15,16,33,37,38 the untestable
exogeneity assumption underlying IVs,10–14 or restricting to
laboratory confirmed positive and negative cases of influenza.7–9
A possible limitation was that all estimates reflect the intention-
to-treat effect of an invitation receipt for a free flu shot, as
vaccination uptake was not available in the registries, and
therefore identify the impact of the vaccination programme and
not the impact of vaccination take-up.39,40 Our estimated 9.8
percentage points (95% CI = 3.5 to16.1; P < 0.01) increase in
vaccination take-up at age 65 can, however, be used to obtain an
indication of the local average treatment effects of vaccination take-
up as there was no evidence for corresponding discontinuities in the
control variables or preventive, health and altruistic behaviour, and
provided the HIS surveys accurately reflect the population in the
administrative register data.18,41 We further note that our
estimates are local at ‘programme-age’ 65 and most likely upper
bounds for those aged 65 and older since antibody response to
influenza vaccination declines with age.42,43We neither can exclude
that the absence of an effect on respiratory deaths and
hospitalizations (ICD J00–J99 and ICD 9 460–519) derives from
the inclusion of non-infectious deaths and hospitalizations, such
as COPD, in these ICD codes. Finally, the absence of a mortality
impact during the non-epidemic period, which includes months
with low and high influenza incidence, indicates that attrition bias
in the hospital register and the HIS surveys must be very small.
In conclusion, we find that the Dutch free vaccination programme
led to considerable cost savings by taking pressure from primary
health care and had a small to negligible effect on hospitalizations
and influenza/pneumonia deaths at age 65.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 Convincing evidence on seasonal influenza vaccination
effectiveness is lacking for individuals aged 65+.
 A regression discontinuity design showed that an invitation
for free influenza vaccination was associated with lower
prescribed medicine use, fewer GP visits and minor
mortality reductions at age 65, but only during influenza-
epidemic months.
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 Invitations for free Influenza vaccination among the 65+
takes pressure off primary health care, but had small
effects on hospitalization and mortality.
References
1 Demicheli V, Jefferson T, De Pietrantonj C, et al. Vaccines for preventing influenza
in the elderly. Cochrane Database Syst Rev 2018;2:CD004876.
2 European Centre for Disease Prevention and Control. Implementation of the
Council Recommendation on seasonal influenza vaccination (2009/1019/EU).
Stockholm: EDC, 2014.
3 Grohskopf LA, Sokolow LZ, Olsen SJ, et al. Prevention and Control of Influenza
with Vaccines: recommendations of the Advisory Committee on Immunization
Practices, United States, 2015–16 Influenza Season. MMWR Morb Mortal Wkly Rep
2015;64:818–25.
4 Baxter R, Lee J, Fireman B. Evidence of bias in studies of influenza vaccine
effectiveness in elderly patients. J Infect Dis 2010;201:186–9.
5 Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza
vaccine effectiveness in seniors. Int J Epidemiol 2006;35:337–44.
6 Michiels B, Govaerts F, Remmen R, et al. A systematic review of the evidence on the
effectiveness and risks of inactivated influenza vaccines in different target groups.
Vaccine 2011;29:9159–70.
7 Belongia E, Simpson M, King J, et al. Variable influenza vaccine effectiveness by
subtype: a systematic review and meta-analysis of test-negative design studies.
Lancet Infect Dis 2016;16:942–51.
8 Rondy M, El Omeiri N, Thompson M, et al. Effectiveness of influenza vaccines in
preventing severe influenza illness among adults: a systematic review and meta-
analysis of test-negative design case-control studies. J Infect 2017;75:381–94.
9 Darvishian M, van den Heuvel ER, Bissielo A, et al. Effectiveness of seasonal
influenza vaccination in community-dwelling elderly people: an individual
participant data meta-analysis of test-negative design case-control studies. Lancet
Respir Med 2017;5:200–11.
10 Yoo BK, Frick KD. The instrumental variable method to study self-selection
mechanism: a case of influenza vaccination. Value Health 2006;9:114–22.
11 Groenwold RHH, Hak E, Klungel OH, Hoes AW. Instrumental variables in
influenza vaccination studies: mission impossible? Value Health 2010;13:132–7.
12 Wong K, Campitelli MA, Stukel TA, et al. Estimating influenza vaccine effectiveness
in community-dwelling elderly patients using the instrumental variable analysis
method. Arch Intern Med 2012;172:484–91.
13 Brookhart MA, McGrath L. The influenza vaccine in elderly persons. A shot in the
dark? Arch Intern Med 2012;172:492–3.
14 Ward CJ. Influenza vaccination campaigns: is an ounce of prevention worth a
pound of cure? Am Econ J Appl Econ 2014;6:38–72.
15 Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations
in persons aged 50 years and older. Vaccine 2010;28:7267–72.
16 Armstrong BG, Mangtani P, Fletcher A, et al. Effect of influenza vaccination on
excess deaths occurring during periods of high circulation of influenza: cohort study
in elderly people. BMJ 2004;329:660.
17 Halloran ME, Struchiner CJ. Study designs for dependent happenings. Epidemiology
1991;2:331–8.
18 Lee DS, Lemieux T. Regression discontinuity designs in economics. J Econ Lit
2010;48:281–355.
19 Bor J, Moscoe E, Mutevedzi P, et al. Regression discontinuity designs in
epidemiology. Causal inference without randomized trials. Epidemiology
2014;25:729–37.
20 Venkataramani AS, Bor J, Jena AB. Regression discontinuity designs in healthcare
research. BMJ 2016;352:i1216.
21 Van Essen GA, Kuyvenhoven MM, Masurel N, et al. Influenza vaccination in the
Netherlands: a successful system approach. Int Congr Ser 2001;1219:689–95.
22 Mereckiene J, Cotter S, Nicoll A, et al. Seasonal influenza immunisation in Europe.
Overview of recommendations and vaccination coverage for three seasons: pre-
pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro
Surveill 2014;19:20780.
23 Imbens GW, Kalyanaraman K. Optimal bandwidth choice for the regression
discontinuity estimator. Rev Econ Stud 2012;79:933–59.
24 McCrary J. Manipulation of the running variable in the regression discontinuity
design: a density test. J Econom 2008;142:698–714.
25 Zellner A. An efficient method of estimating seemingly unrelated regressions and
tests for aggregation bias. J Am Stat Assoc 1962;57:348–68.
26 Netherlands Institute for Health Services Research. Zorgregistraties eerste lijn.
Gegevens aanvragen. Available at: https://www.nivel.nl/nl/nivel-zorgregistraties-
eerste-lijn/gegevens-aanvragen (20 May 2015, date last accessed).
27 Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med
2008;121:258–64.
28 Carman KG, Mosca I. Who takes up free flu shots? Examining the effects of an
expansion in coverage. Economist 2014;162:1–17.
29 Voordouw A, Sturkenboom M, Dieleman J, et al. Annual revaccination against
influenza and mortality risk in community-dwelling elderly persons. JAMA
2004;292:2089–95.
30 Voordouw B, van der Linden P, Simonian S, et al. Influenza vaccination in
community-dwelling elderly. Impact on mortality and influenza-associated
morbidity. Arch Intern Med 2003;163:1089–94.
31 Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in
hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med
2003;348:1322–32.
32 Nichol KL, Nordin J, Nelson DB, et al. Effectiveness of influenza vaccine in the
community-dwelling elderly. N Engl J Med 2007;357:1373–81.
33 Mangtani P, Cumberland P, Hodgson CR, et al. cohort study of the effectiveness of
influenza vaccine in older people, performed using the United Kingdom general
practice research database. J Infect Dis 2004;190:1–10.
34 Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Kosten
Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor
economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. College
voor zorgverzekeringen.
35 Hak E, van Loon S, Buskens E, et al. Design of the Dutch Prevention of Influenza,
Surveillance and Management (PRISMA) study. Vaccine 2003;1:1719–24.
36 Lopez Bernal JA, Andrews N, Amirthalingam G. The use of quasi-experimental
designs for vaccine evaluation. Clin Infect Dis 2019;68:1769–76.
37 McGrath LJ, Kshirsagar AV, Cole SR, et al. Influenza vaccine effectiveness in patients
on hemodialysis: an analysis of a natural experiment. Arch Intern Med
2012;172:548–54.
38 McDonald SA, van Asten L, van der Hoek W, et al. The impact of national
vaccination policy changes on influenza incidence in the Netherlands. Influenza
Other Respi Viruses 2016;10:76–85.
39 Battistin E, Brugiavini A, Rettore E, Weber G. The retirement consumption
puzzle: evidence from a regression discontinuity approach. Am Econ Rev
2009;99:2209–26.
References 40–43 are included in the Supplementary online.
280 European Journal of Public Health
D
ow
nloaded from
 https://academ
ic.oup.com
/eurpub/article/30/2/275/5736260 by guest on 09 Septem
ber 2020
. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
The European Journal of Public Health, Vol. 30, No. 2, 281–285
 The Author(s) 2020. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.
doi:10.1093/eurpub/ckz238 Advance Access published on 29 January 2020
. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
Rotavirus vaccination impact, Ireland, implications for
vaccine confidence and screening
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Background: Rotavirus vaccine efficacy is well established. However, it is important to consistently demonstrate
the positive impact of vaccination programmes in order to optimize uptake rates and combat vaccine hesitancy.
Methods: Routine data were used to examine rotavirus vaccine effectiveness in Ireland, including changes in
age-specific crude incidence rates (CIRs), hospitalizations and hospital length of stay. National intussusception
incidence was interrogated. Vaccination status of vaccine-eligible cases of rotavirus infection was determined.
Results: Nationally, a reduction in the CIR of rotavirus infection of 77.2% [95% confidence interval (CI) 57.8–
88.5%, P<0.001] was observed post-inclusion of the rotavirus vaccine in the primary immunization schedule. A
decrease in hospitalizations of 85.5% (95% CI 79.3–90.2%, P<0.001), 86.5% (95% CI 82.9–89.4%, P<0.001) and
78.5% (95% CI 74.7–81.9%, P<0.001) was observed in children aged <1, <2 and <5 years, respectively. Most
hospitalizations occurred in infants too young to have been vaccinated. There was no significant difference in
median length of stay for children hospitalized with rotavirus infection. Decreased CIRs and hospitalization rates
in unvaccinated children aged between 2 and 5 years suggest community immunity. Vaccine non-protection was
0.13%. No increase in the national CIR of intussusception was observed. Conclusions: Inclusion of the rotavirus
vaccine in the Irish primary immunization schedule has resulted in a significant reduction in the burden of
rotavirus infection. However, vaccine hesitancy remains a concern. With new vaccination programmes, risk of
vaccine harms should be considered and mitigated in order to protect individuals and the integrity of the
programme.
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Introduction
Rotavirus is a leading cause of acute gastroenteritis in paediatricpopulations, resulting in considerable morbidity and healthcare
utilization.1–3 Rotavirus crude incidence rates (CIRs) are high in
Ireland with 2308 cases notified in 2017; a national CIR of 48.5/
100 000 population.4 There is significant geographical variation in
CIRs, with the highest and lowest regional CIRs observed in the
Midlands (78.0/100 000 population) and North-East (33.9/100 000
population), respectively.
Following a recommendation from the World Health
Organization (WHO) in April 2009, 86 countries have included
rotavirus vaccination in their national primary immunization
schedules,2 with associated reductions in rotavirus-attributable
morbidity.1,3,5,6 In December 2016, Ireland introduced the
RotarixTM vaccine for all infants born on or after the first of
October 2016.7 RotarixTM is a live attenuated monovalent vaccine
administered orally in two doses at 2 and 4 months of age.7
Inclusion of a new vaccine in the national immunization schedule
is associated with financial and administrative challenges, including
the cost of providing the vaccine and the need to define and address
barriers to access. Vaccine hesitancy poses an additional challenge
and may be exacerbated by vaccine controversy arising from
misinformation, disinformation and genuine cases of vaccine
harm. While the clinical effectiveness of the rotavirus vaccine is
established,2,8–10 historic and current vaccine controversies
demonstrate that public opinion has a considerable impact on
uptake rates.11–15 It is, therefore, important that policymakers and
health professionals act to combat vaccine hesitancy by consistently
demonstrating and communicating the positive impact of
population-level immunization. The integrity of immunization
programmes can be further protected by ensuring potential
vaccine harms are identified and the risk of such harms mitigated
in so far as is practicable. For the rotavirus vaccine, potential harms
include increased risk of intussusception and risk of severe
iatrogenic vaccine strain infection if administered to an infant
with an undiagnosed primary immunodeficiency disorder (PID).
The aims of the study were to:
(1) demonstrate the impact of inclusion of the rotavirus vaccine in
the Irish primary immunization schedule, including vaccine
effectiveness [defined as direct (vaccine induced) and indirect
(population related) protection during routine use16] and
incidence of intussusception; and
(2) consider how potential harms associated with rotavirus
vaccination might be mitigated to protect individuals and
public confidence in immunization programmes.
The objectives of the study were to:
(1) determine the vaccine effectiveness of the rotavirus vaccine
following its inclusion in the primary immunization schedule.
Measures of vaccine effectiveness examined include:
 changes in age-specific CIRs of rotavirus infection,
 changes in age-specific hospitalizations and bed days used
(BDU) for rotavirus infection and
 changes in rotavirus-attributable morbidity, using hospital
length of stay (LOS) as a proxy;
(2) determine the vaccination status of vaccine-eligible cases of
rotavirus infection in the Midlands region post-inclusion of
the vaccine in the primary immunization schedule; and
(3) identify whether the national CIR of intussusception has
increased post-inclusion of the rotavirus vaccine in the
primary immunization schedule.
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